Literature DB >> 27067086

Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.

Arman Qamar1, Deepak L Bhatt2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27067086     DOI: 10.1161/CIRCULATIONAHA.115.018549

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2.

Authors:  Charles A Herzog
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-25       Impact factor: 8.237

2.  Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme-A Post Hoc Analysis.

Authors:  Yung-Chuan Huang; Yu-Chen Cheng; Mao-Jhen Jhou; Mingchih Chen; Chi-Jie Lu
Journal:  J Pers Med       Date:  2022-05-06

Review 3.  Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?

Authors:  Benjamin E Peterson; Deepak L Bhatt
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

4.  Efficacy of Statin Therapy Related to Baseline Renal Function in Patients with Rheumatic Heart Disease Undergoing Cardiac Surgery.

Authors:  Rongjun Zou; Wanting Shi; Jun Tao; Xifeng Lin; Dingwen Zhang; Songran Yang; Ping Hua
Journal:  Biomed Res Int       Date:  2018-04-15       Impact factor: 3.411

5.  Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Authors:  Shinya Goto; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Helena Dominguez; Laura Illingworth; Harry Gibbs; Samuel Z Goldhaber; Shinichi Goto; Zhi-Cheng Jing; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Toon Wei Lim; Seil Oh; Jitendra P S Sawhney; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.